Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rubiada Wani

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
European Journal of Pharmacology|December 21, 2020
Targeting EHMT2/ G9a for cancer therapy: Progress and perspectiveSuraya Jan, Mohd Ishaq Dar, Rubiada Wani, et al.
Cellular Signalling|November 6, 2019
Differentiation of human neuroblastoma cell line IMR-32 by sildenafil and its newly discovered analogue IS00384Mohd I Dar, Suraya Jan, G Lakshma Reddy, et al.
Biochimica Et Biophysica Acta. General Subjects|June 9, 2023
Discovery of SDS-347 as a specific peptide competitive inhibitor of G9a with promising anti-cancer potentialSuraya Jan, Mohd I Dar, Gauri Shankar, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
European Journal of Pharmacology|December 21, 2020
Targeting EHMT2/ G9a for cancer therapy: Progress and perspectiveSuraya Jan, Mohd Ishaq Dar, Rubiada Wani, et al.
Cellular Signalling|November 6, 2019
Differentiation of human neuroblastoma cell line IMR-32 by sildenafil and its newly discovered analogue IS00384Mohd I Dar, Suraya Jan, G Lakshma Reddy, et al.
Biochimica Et Biophysica Acta. General Subjects|June 9, 2023
Discovery of SDS-347 as a specific peptide competitive inhibitor of G9a with promising anti-cancer potentialSuraya Jan, Mohd I Dar, Gauri Shankar, et al.
Pageof 1